News & Analysis as of

Medicaid › Drug Pricing › Legislative Agendas

Medicaid is a partnership program between states and the federal government to provide healthcare coverage for lower income individuals, people with disabilities, older people, and certain families with... more +
Medicaid is a partnership program between states and the federal government to provide healthcare coverage for lower income individuals, people with disabilities, older people, and certain families with children.  less -
Brownstein Hyatt Farber Schreck

Summary of Health Care Provisions in the “One Big Beautiful Bill Act”

Brownstein Hyatt Farber Schreck on

On May 22, the U.S. House of Representatives passed the One Big Beautiful Bill Act (H.R. 1), an extensive budget reconciliation package that advances President Trump’s plan to enact his economic agenda. After a series of...more

McDermott+

Healthcare Preview for the Week of: May 12, 2025

McDermott+ on

Reconciliation Text Is Here - Late Sunday night, May 11, 2025, the House Committee on Energy and Commerce released the much-anticipated budget reconciliation bill text ahead of its scheduled markup on May 13, 2025. ...more

Spilman Thomas & Battle, PLLC

The Health Record - Healthcare Law Insights, V 2, Issue 5, April 2025

Spilman Thomas & Battle, PLLC on

Welcome to our fifth issue of 2025 of The Health Record -- our healthcare law insights e-newsletter. In this edition, we look at the effect tariffs could have on pharmaceuticals, the rise in healthcare facilities as the...more

McDermott+

McDermott+ Check-Up: April 11, 2025

McDermott+ on

THIS WEEK’S DOSE - House Passes Concurrent Budget Resolution for Reconciliation Process. Passage of the resolution didn’t resolve the policy differences between the House and the Senate. Those still need to be addressed as...more

McDermott Will & Schulte

This Week in 340B: July 2 – 8, 2024

McDermott Will & Schulte on

Find this week’s updates on 340B litigation to help you stay in the know on how 340B cases are developing across the country. Each week we comb through the dockets of more than 50 340B cases to provide you with a quick...more

McDermott+

McDermottPlus Check-Up: April 17, 2024

McDermott+ on

House Energy & Commerce Health Subcommittee Holds Hearing on Cybersecurity. During the hearing, there was bipartisan concern about UnitedHealth Group’s response to the Change Healthcare cyberattack and consensus around the...more

Epstein Becker & Green

Last Call for Comments on Bipartisan Discussion Draft SUSTAIN Act: Shaping 340B for the Future

Epstein Becker & Green on

Only a few days remain for stakeholders—which includes drug manufacturers, patients, health care providers, pharmacies and others— to take advantage of a rare opportunity to influence the statutory contours of the 340B Drug...more

Holland & Knight LLP

Holland & Knight Health Dose: October 3, 2023

Holland & Knight LLP on

Holland & Knight Health Dose is an in-depth weekly dose of legislative and regulatory insights to keep stakeholders abreast of happenings in Washington, D.C., impacting the health sector. ...more

McDermott+

McDermottPlus Check-Up: June 16, 2023

McDermott+ on

The House and Senate were both in session this week, with healthcare activity continuing at the committee level. The House Energy and Commerce Committee held hearings on the Pandemic and All Hazards Preparedness Act (PAHPA)...more

Holland & Knight LLP

2022 Congressional Outlook and Top 10 Federal Health Policy Issues to Watch

Holland & Knight LLP on

As Congress reconvenes, it faces a packed agenda in a legislative year that will be shortened by the upcoming midterm elections and remains buffeted by the persistent coronavirus pandemic. The list of healthcare priorities is...more

Patrick Malone & Associates P.C. | DC Injury...

U.S. panel rips drug prices as ‘unsustainable, unjustifiable, unfair’

Patrick Malone & Associates P.C. | DC Injury... on

Regular folks have known it, chapter and verse, forever. They experience it every time they pay for their prescription drugs. But Democrats in the U.S. House report in a 269-page study that they have spent three years on,...more

Hogan Lovells

Ramping up the drug pricing debate: Dueling bills and paying for health care infrastructure

Hogan Lovells on

The U.S. House of Representatives is considering dueling proposals related to drug pricing under Medicaid and Medicare, including the Republican-led H.R. 19, the “Lower Costs, More Cures Act of 2021” and a reintroduced...more

McDermott Will & Schulte

340B in 2021: What Covered Entities and Their Partners Need to Know Now

McDermott Will & Schulte on

Since March 2010, increased growth in the 340B Program has been accompanied by increased scrutiny from state and federal governments and conflicts between various 340B Program stakeholders. A transition in U.S. Department of...more

McDermott Will & Schulte

[Webinar] 340B in 2021: What Covered Entities and Their Partners Need to Know Now - March 18th, 2:00 pm - 3:00 pm ET

McDermott Will & Schulte on

This must-attend webinar will give 340B covered entities and their partners up-to-the-minute insights into the most pressing issues affecting their business today and the trends that will shape the market tomorrow. Our...more

K&L Gates LLP

K&L Gates Triage: Looking Ahead to 2020: Developing Issues in Pharmacy Law and the 340B Drug Pricing Program

K&L Gates LLP on

In this episode, Ryan Severson and Victoria Hamscho discuss recent developments in pharmaceutical pricing and the 340B Drug Pricing Program heading into 2020, including reimbursement cuts for 340B drugs under the Outpatient...more

Brownstein Hyatt Farber Schreck

End-of-Year Spending and Health Care Extenders Package Overview

Brownstein Hyatt Farber Schreck on

House and Senate lawmakers came to a bipartisan agreement on an end-of-year spending deal that will fund the government for FY 2020. The $1.37 trillion package includes a total of $738 billion in funding for the military and...more

Akin Gump Strauss Hauer & Feld LLP

Battle Lines Drawn with Release of Speaker’s Drug Pricing Plan

Akin Gump Strauss Hauer & Feld LLP on

[co-authors: Sean Feely, Senior Public Policy Specialist and Julie E. Nolan, Senior Policy Advisor] • On September 19, Speaker Pelosi released a drug pricing plan that includes proposals for Medicare direct price...more

Baker Donelson

Grassley Finance Committee Agenda Highlights Oversight

Baker Donelson on

Senator Charles "Chuck" Grassley, Chairman of the Senate Finance committee which has jurisdiction over Medicare and Medicaid as well as taxation and other revenue measures, has less than 18 months left in his tenure as...more

Foley & Lardner LLP

2019 Health Care Industry Outlook

Foley & Lardner LLP on

A new wave of change is poised to disrupt the way health care is delivered in the United States. This time around, the disruption is coming not from lawmakers or the president, who have struggled to repeal or improve upon...more

Patrick Malone & Associates P.C. | DC Injury...

Really? Trump embraces Europe’s price controls to fight high U.S. drug costs

Patrick Malone & Associates P.C. | DC Injury... on

Days before politicians will face voters who tell pollsters they’re angry and upset about health care issues, President Trump made his first visit to the nation’s giant Health and Human Services Department to roll out a...more

Mintz - Health Care Viewpoints

Health Care Weekly Preview from ML Strategies – October 2018 #3

Mintz - Health Care Viewpoints on

Last week concluded the Senate’s time in Washington prior to the lame duck session. With both the House and the Senate back home and focused on campaigning, we turn our attention to action from the Administration. As of...more

Mintz - Health Care Viewpoints

Health Care Weekly Preview from ML Strategies – September 2018 #3

Mintz - Health Care Viewpoints on

This week is already well under way with drama unfolding on both sides of Capitol Hill. First, the allegations against Supreme Court nominee Brett Kavanaugh upended his chances for a swift confirmation as several Republican &...more

Foley & Lardner LLP

Health Care Policy Newsletter - July 2018 #3

Foley & Lardner LLP on

Foley & Lardner LLP’s (“Foley”) Bipartisan Public Policy Team is pleased to share our “Public Policy Weekly* Health Care Newsletter” in which we compile the latest Health Care policy news and legislation. *Please note that we...more

Foley & Lardner LLP

Health Care Policy Newsletter - July 2018

Foley & Lardner LLP on

Foley & Lardner LLP’s (“Foley”) Bipartisan Public Policy Team is pleased to share our “Public Policy Weekly* Health Care Newsletter” in which we compile the latest Health care policy news and legislation. *Please note that we...more

Foley & Lardner LLP

Health Care Policy Newsletter - June 2018 pt 3

Foley & Lardner LLP on

Foley & Lardner LLP’s (“Foley”) Bipartisan Public Policy Team is pleased to share our “Public Policy Weekly* Health Care Newsletter” in which we compile the latest Health care policy news and legislation. *Please note that we...more

42 Results
 / 
View per page
Page: of 2
Next »

"My best business intelligence, in one easy email…"

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:
Sign up Log in
*By using the service, you signify your acceptance of JD Supra's Privacy Policy.
- hide
- hide